semaglutide and concerta Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),

Slowing an infusion may help some rate-related symptomsbut does not diagnose them Chest symptoms, low blood pressure, breathing difficulty, severe pain, or neurologic symptoms require assessment rather than automatic continuation at a slower rate

, -1 700 % 2019 2023

American Medical Association: Questions Patients May Have About Weight Loss Drugs Stanford Health Care: Weight Loss Maintenance Adam Gilden, MD, MSCE Medical Reviewer Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me

Common GLP-1 Injections and Their FDA-Approved Uses Here are several GLP-1 receptor agonists currently available as injections: These medications must be prescribed by a licensed provider following an evaluation of your medical history, weight-related conditions, and current medications

Talking openly about this with a trusted professional can be helpful

Other concerning symptoms that necessitate medical consultation include: Severe abdominal distension or inability to pass gas/stool (possible ileus or bowel obstruction) Nausea that worsens rather than improves after 812 weeks Inability to maintain adequate nutrition or hydration Unintentional weight loss exceeding clinical targets New or worsening heartburn or reflux symptoms Visual changes (especially with rapid blood sugar improvement) Severe headache or altered mental status Signs of gallbladder disease (right upper quadrant pain, especially after eating) Hypoglycemia symptoms if taking insulin or sulfonylureas Patients should generally not discontinue GLP-1 medications without medical guidance, except in emergencies such as suspected pancreatitis or severe allergic reaction